<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<article xlink="http://www.w3.org/1999/xlink" dtd-version="1.0" article-type="healthcare" lang="en"><front><journal-meta><journal-id journal-id-type="publisher">IJCRR</journal-id><journal-id journal-id-type="nlm-ta">I Journ Cur Res Re</journal-id><journal-title-group><journal-title>International Journal of Current Research and Review</journal-title><abbrev-journal-title abbrev-type="pubmed">I Journ Cur Res Re</abbrev-journal-title></journal-title-group><issn pub-type="ppub">2231-2196</issn><issn pub-type="opub">0975-5241</issn><publisher><publisher-name>Radiance Research Academy</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">4889</article-id><article-id pub-id-type="doi"/><article-id pub-id-type="doi-url"> https://doi.org/10.31782/IJCRR.2026.18201</article-id><article-categories><subj-group subj-group-type="heading"><subject>Healthcare</subject></subj-group></article-categories><title-group><article-title>&#13;
	Evaluation of Treatment Outcomes and Safety of Erythrocytapheresis versus Phlebotomy in Adults with Hereditary Hemochromatosis&#13;
&#13;
&#13;
&#13;
	 &#13;
&#13;
&#13;
&#13;
	Patrycja Machno, Aleksandra Salagierska, Zofia Gniadek, Wiktoria Jurczyk-Florkiewicz, Agata Pszczolka, Gabriela Bajor, Kacper Melka, Mikolaj Szulewski, Patryk Matuszczak, Joanna Kozak&#13;
&#13;
&#13;
&#13;
	 &#13;
&#13;
&#13;
&#13;
	 &#13;
&#13;
&#13;
&#13;
	 &#13;
&#13;
</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Machno</surname><given-names>Patrycja</given-names></name></contrib><contrib contrib-type="author"><name><surname>Salagierska</surname><given-names>Aleksandra</given-names></name></contrib><contrib contrib-type="author"><name><surname>Gniadek</surname><given-names>Zofia</given-names></name></contrib><contrib contrib-type="author"><name><surname>Jurczyk-Florkiewicz</surname><given-names>Wiktoria</given-names></name></contrib><contrib contrib-type="author"><name><surname>Pszczolka</surname><given-names>Agata</given-names></name></contrib><contrib contrib-type="author"><name><surname>Bajor</surname><given-names>Gabriela</given-names></name></contrib><contrib contrib-type="author"><name><surname>Melka</surname><given-names>Kacper</given-names></name></contrib><contrib contrib-type="author"><name><surname>Szulewski</surname><given-names>Mikolaj</given-names></name></contrib><contrib contrib-type="author"><name><surname>Matuszczak</surname><given-names>Patryk</given-names></name></contrib><contrib contrib-type="author"><name><surname>Kozak</surname><given-names>Joanna</given-names></name></contrib></contrib-group><pub-date pub-type="ppub"><day>30</day><month>01</month><year>2026</year></pub-date><volume>)</volume><issue/><fpage>1</fpage><lpage>6</lpage><permissions><copyright-statement>This article is copyright of Popeye Publishing, 2009</copyright-statement><copyright-year>2009</copyright-year><license license-type="open-access" href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.</license-p></license></permissions><abstract><p>&#13;
	Hereditary hemochromatosis is a common genetic disorder characterized by progressive iron overload that may lead to multi organ damage if untreated. The aim of this review was to compare the efficacy, safety, and treatment characteristics of erythro cytapheresis and phlebotomy in adults with HFE-related hereditary hemochromatosis. A literature search was conducted using PubMed and Google Scholar to identify studies published after 2012 that directly compared both treatment modalities in adult patients. Available evidence indicated that both phlebotomy and erythrocytapheresis were effective in reducing iron overload and achieved comparable long-term control of serum ferritin and transferrin saturation. Erythrocytapheresis allowed removal of a greater amount of iron per procedure and was associated with fewer treatment sessions and a shorter induction phase. Adverse events were predominantly mild and transient. Although the cost per procedure was higher for erythrocytapheresis, overall treat ment costs appeared comparable when reduced procedure frequency and indirect costs were considered. Phlebotomy remains the first-line therapy for most patients; however, erythrocytapheresis represented a safe and effective alternative in selected individuals, particularly when rapid iron depletion or improved treatment tolerability was required.&#13;
&#13;
</p></abstract><kwd-group><kwd>Erythrocytapheresis; Hereditary hemochromatosis; Iron overload; Phlebotomy; Safety; Treatment outcomes</kwd></kwd-group></article-meta></front></article>
